Quantum Sensor Revolutionizes Cancer Detection with Ultra-Low Sensitivity
A groundbreaking innovation in cancer detection has emerged, thanks to a team of researchers who have engineered a quantum sensor capable of identifying ultra-low levels of cancer biomarkers in blood. This cutting-edge technology, detailed in the Optica journal, showcases the potential for early cancer detection, even when biomarker concentrations are at their lowest.
The sensor's unique design combines DNA nanostructures, quantum dots, and CRISPR gene editing technology. By harnessing the power of second harmonic generation (SHG), a light-based technique, the sensor can detect faint biomarker signals that conventional methods often miss. Han Zhang, PhD, a distinguished professor and director of the College of Physics and Optoelectronic Engineering, explains, "Our approach could simplify disease treatment, potentially boost survival rates, and reduce healthcare costs."
The sensor's foundation lies in a flat layer of molybdenum disulfide, a semiconducting material ideal for supporting SHG. DNA nanostructures in the shape of pyramids are used to precisely position quantum dots on the sensor's surface, amplifying the SHG signal. CRISPR technology then enables the sensor to recognize specific targets, with the Cas12a protein cutting the DNA structures holding the quantum dots when it identifies its target, thereby reducing the SHG signal.
This method's strength lies in its ability to minimize background noise, allowing for the detection of ultra-low biomarker concentrations. Unlike traditional detection methods that require DNA or RNA amplification, these quantum sensors can directly detect targets, making the process faster, more affordable, and error-resistant.
The team successfully tested the sensor by programming it to detect miRNA-21, a lung cancer biomarker. Serum samples from lung cancer patients confirmed the sensor's effectiveness in identifying the target biomarker. Zhang highlights, "The sensor's high specificity and performance demonstrate the power of integrating optics, nanomaterials, and biology."
Looking ahead, the researchers aim to refine the sensor design, making it smaller and more portable. Their ultimate goal is to create a device that can be easily used in clinical and remote settings, enabling early cancer detection and personalized treatment options. Zhang envisions, "This method could facilitate simple blood screenings for lung cancer before tumors become visible on CT scans, and it could also enable daily or weekly biomarker monitoring to assess drug efficacy."
